AP5Z1 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma cell line. This product features a targeted disruption of the AP5Z1 gene, generating a loss-of-function model for investigating endosomal-lysosomal trafficking. The polyclonal format comprises a heterogeneous pool of edited cells, avoiding clonal selection artifacts and reflecting the complexity of gene knockout at a population level. These cells are suitable for functional genomics studies where pooled genetic perturbations are desirable for robust phenotypic screening.
The HT29 cell line is an established epithelial model derived from a human colon adenocarcinoma. It harbors well-characterized mutations in the APC and TP53 tumor suppressor genes, along with other cancer-associated genetic alterations, recapitulating key molecular features of colorectal carcinogenesis. HT29 cells retain the ability to undergo enterocytic differentiation, making them a versatile platform for studying intestinal epithelial biology, drug responses, and signal transduction in the context of colorectal cancer.
AP5Z1 encodes the ?? subunit of the AP-5 adaptor protein complex, which is essential for clathrin-mediated retrograde transport from late endosomes to lysosomes. The AP-5 complex includes AP5B1, AP5M1, and AP5S1, and is regulated by upstream factors such as TFEB, MTOR, and cellular stress signals. AP5Z1 functions downstream of these regulators to mediate sorting of lysosomal membrane proteins (e.g., LAMP1) and autophagic cargo. Its disruption leads to lysosomal dysfunction, impaired autophagy, and accumulation of undegraded substrates. AP5Z1 also interacts with SPG11 and SPG15, linking it to pathways involved in hereditary spastic paraplegia.
In the HT29 colorectal cancer background, AP5Z1 knockout provides a clinically relevant model to study the intersection of endosomal-lysosomal dysfunction and tumor biology. Aberrant endosomal trafficking can influence cancer cell growth, survival, and drug sensitivity by altering receptor recycling and metabolic adaptation. This model allows dissection of how AP5Z1 loss cooperates with existing APC and TP53 mutations to drive colorectal cancer phenotypes. Additionally, it serves as a platform for investigating neurodegenerative disease mechanisms, as AP5Z1 mutations cause hereditary spastic paraplegia type 48, enabling cross-disease analysis of lysosomal pathology.
Researchers can employ these polyclonal knockout cells in a variety of experimental applications. Typical assays include western blotting for AP5Z1 to confirm knockout, immunofluorescence staining for LAMP1 to assess lysosomal distribution, and LC3-II turnover assays to measure autophagy flux. Endocytosis studies with EGF or transferrin can probe clathrin-mediated uptake, while lysosomal pH measurements reveal functional defects. This model is also suitable for small-molecule screens targeting lysosomal pathways and for investigating drug resistance mechanisms in colorectal cancer. For additional technical information or custom inquiries, please contact Ascent Research.
